We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Possible Therapeutic Use for a Cardiac RNA Fragment

By Biotechdaily staff writers
Posted on 05 Apr 2007
Cardiac disease researchers have found that the gene coding for the alpha-myosin heavy chain (MHC) contractile protein also produces an RNA fragment that regulates cardiac growth and gene expression in response to stress and hormonal signaling.

The heart responds to diverse forms of stress by hypertrophic growth accompanied by fibrosis and eventual diminution of contractility due to reduced production of alpha-MHC and increased production of the less efficient beta-MHC contractile proteins.

To study the molecular basis for the heart's response to stress, investigators at the University of Texas Southwestern Medical Center (Dallas, USA) genetically engineered a strain of mice to lack the segment of the alpha-MHC gene that produces the miR-208 RNA fragment. More...
This mouse population was then exposed to various chemical or physical stress factors, and the subsequent effect on the animals' hearts was determined. Results published in the March 22, 2007, online edition of Science Express revealed that the engineered mice lacking miR-208 maintained normal heart morphology with low levels of beta-MHC. This was in contrast to normal mice exposed to the same stress factors that suffered heart damage and increased beta-MHC production.

"We have discovered a new and completely unanticipated mechanism for regulating the contractility of the heart,” said senior author Dr. Eric Olson, professor of molecular biology at the University of Texas Southwestern Medical Center. "We are very excited about the therapeutic implications, but we still have much work left to do. Although miR-208 appears to damage the heart during stress, it may have beneficial functions for maintaining normal action of heart muscle cells. So any therapeutic approach would probably need to target its harmful stress responses while leaving normal function alone.”


Related Links:
University of Texas Southwestern Medical Center

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Urine Analyzer
respons® UDS100
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.